ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)

About ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACAD
  • CUSIP: N/A
  • Web:
  • Market Cap: $3.7 billion
  • Outstanding Shares: 122,046,000
Average Prices:
  • 50 Day Moving Avg: $27.92
  • 200 Day Moving Avg: $32.16
  • 52 Week Range: $20.68 - $40.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.79
  • P/E Growth: -0.37
Sales & Book Value:
  • Annual Revenue: $32.61 million
  • Price / Sales: 113.44
  • Book Value: $3.75 per share
  • Price / Book: 8.08
  • EBIDTA: ($309,030,000.00)
  • Net Margins: -948.93%
  • Return on Equity: -63.07%
  • Return on Assets: -58.40%
  • Current Ratio: 10.82%
  • Quick Ratio: 10.74%
  • Average Volume: 1.58 million shs.
  • Beta: 3.93
  • Short Ratio: 12.66
Frequently Asked Questions for ACADIA Pharmaceuticals (NASDAQ:ACAD)

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.72) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.73) by $0.01. The company earned $15.30 million during the quarter, compared to analysts' expectations of $15.17 million. ACADIA Pharmaceuticals had a negative return on equity of 63.07% and a negative net margin of 948.93%. During the same quarter in the previous year, the business earned ($0.45) earnings per share. View ACADIA Pharmaceuticals' Earnings History.

When will ACADIA Pharmaceuticals make its next earnings announcement?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for ACADIA Pharmaceuticals.

Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2017?

14 analysts have issued 1-year price objectives for ACADIA Pharmaceuticals' stock. Their predictions range from $25.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $43.00 in the next year. View Analyst Ratings for ACADIA Pharmaceuticals.

What are analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (7/17/2017)
  • 2. Needham & Company LLC analysts commented, "Acadia reported $11.9M in 4Q16 Nuplazid sales, above our $9.0M estimate. Mgmt noted steady growth in number of prescribers, repeat prescribers, and new patients. Company also announced plan to expand sales force by 20 reps to address long-term care opportunity. There are no immediate plans to provide 2017 sales guidance. We believe stock is attractive given Nuplazid launch trajectory and likelihood for label expansion in long-term. Stock likely to be driven by sales in 2017 and Phase 2/3 results in other indications in 2018/ 2019. Acadia may be an attractive M&A target. BUY." (3/1/2017)

Who are some of ACADIA Pharmaceuticals' key competitors?

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:

  • Stephen R. Biggar M.D. Ph.D., Chairman of the Board
  • Stephen R. Davis, President, Chief Executive Officer, Director
  • Todd S. Young, Executive Vice President, Chief Financial Officer
  • Glenn F. Baity, Executive Vice President, General Counsel, Secretary
  • Srdjan Stankovic M.D., Executive Vice President, Head - Research and Development
  • Michael J. Yang, Executive Vice President, Chief Commercial Officer
  • Edmund P. Harrigan M.D., Director
  • Julian C. Baker, Independent Director
  • Laura A. Brege, Independent Director
  • James M. Daly, Independent Director

Who owns ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (22.10%), Harvey Capital Management Inc. (0.19%), Handelsbanken Fonder AB (0.15%), Handelsinvest Investeringsforvaltning (0.05%), Creative Planning (0.02%) and Aperio Group LLC (0.01%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Edmund Harrigan, Glenn Baity, Leslie L Iversen, LP 14159 and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Who sold ACADIA Pharmaceuticals stock? Who is selling ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Aperio Group LLC and Hollencrest Securities LLC. Company insiders that have sold ACADIA Pharmaceuticals stock in the last year include Glenn Baity and Terrence O Moore. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Who bought ACADIA Pharmaceuticals stock? Who is buying ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Handelsinvest Investeringsforvaltning, Handelsbanken Fonder AB, Legato Capital Management LLC, Harvey Capital Management Inc. and Creative Planning. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Edmund Harrigan and LP 14159. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy ACADIA Pharmaceuticals stock?

Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $30.31.

MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  403 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  548
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $43.00 (41.87% upside)

Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Rodman & RenshawReiterated RatingBuy$60.00LowView Rating Details
5/10/2017HC WainwrightReiterated RatingBuyLowView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingBuy$47.00LowView Rating Details
4/5/2017Needham & Company LLCReiterated RatingBuy$49.00LowView Rating Details
2/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/AView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$49.00 -> $48.00N/AView Rating Details
1/24/2017Cowen and CompanyReiterated RatingOutperform$42.00N/AView Rating Details
1/11/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
12/28/2016Leerink SwannReiterated RatingMarket Perform$29.00N/AView Rating Details
11/11/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$28.00N/AView Rating Details
11/8/2016Bank of America CorporationUpgradeNeutral -> Buy$35.00N/AView Rating Details
10/19/2016Roth CapitalReiterated RatingNeutral$25.00N/AView Rating Details
8/10/2016JMP SecuritiesReiterated RatingBuy$45.00N/AView Rating Details
8/5/2016AegisDowngradeBuy -> Hold$54.00 -> $41.00N/AView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Earnings by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Earnings History by Quarter for ACADIA Pharmaceuticals (NASDAQ ACAD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017($0.72)N/AView Earnings Details
5/9/2017Q1 2017($0.73)($0.72)$15.17 million$15.30 millionViewListenView Earnings Details
2/28/2017Q416($0.65)($0.65)$9.05 million$12.00 millionViewListenView Earnings Details
11/7/2016Q316($0.56)($0.61)$2.90 million$5.30 millionViewListenView Earnings Details
8/4/2016Q216($0.49)($0.63)$0.71 million$0.97 millionViewListenView Earnings Details
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details
5/7/2015Q115($0.25)($0.40)$0.09 millionViewListenView Earnings Details
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details
11/10/2014Q3($0.12)($0.25)$0.02 millionViewListenView Earnings Details
8/5/2014Q2($0.17)($0.22)$0.10 million$0.03 millionViewListenView Earnings Details
5/6/2014Q1($0.13)($0.19)$0.50 million$0.03 millionViewListenView Earnings Details
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)
2017 EPS Consensus Estimate: ($2.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.75)($0.53)($0.64)
Q2 20172($0.71)($0.48)($0.60)
Q3 20172($0.72)($0.44)($0.58)
Q4 20172($0.71)($0.39)($0.55)
(Data provided by Zacks Investment Research)


Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 97.18%
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/20/2017Glenn BaityEVPSell38,097$30.00$1,142,910.00View SEC Filing  
6/22/2017Glenn BaityEVPSell1,903$30.00$57,090.00View SEC Filing  
2/16/2017Terrence O. MooreEVPSell157,540$39.77$6,265,365.80View SEC Filing  
12/27/2016Glenn BaityEVPSell9,800$30.46$298,508.00View SEC Filing  
12/20/2016Glenn BaityEVPSell10,000$30.00$300,000.00View SEC Filing  
8/16/2016Edmund HarriganDirectorBuy1,000$32.97$32,970.00View SEC Filing  
8/10/2016Bros. Advisors Lp BakerDirectorBuy1,303,030$33.00$42,999,990.00View SEC Filing  
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.00View SEC Filing  
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.00View SEC Filing  
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.41View SEC Filing  
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.00View SEC Filing  
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.00View SEC Filing  
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.00View SEC Filing  
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.65View SEC Filing  
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.40View SEC Filing  
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.00View SEC Filing  
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Latest Headlines for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateHeadline logoACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Announce Quarterly Sales of $19.59 Million - July 23 at 9:18 AM logoGlenn Baity Sells 38,097 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock - July 21 at 7:11 PM logo7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods - - July 21 at 4:39 PM logo7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods - July 21 at 4:39 PM logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : July 21, 2017 - July 21 at 4:39 PM logo Brokerages Expect ACADIA Pharmaceuticals Inc. (ACAD) Will Announce Earnings of -$0.71 Per Share - July 21 at 2:20 PM logoToday's Research Report Coverage on Biotech Stocks -- ACADIA Pharma, Aduro BioTech, Agios Pharma, and AveXis - PR Newswire (press release) - July 20 at 3:29 PM logoACADIA Pharmaceuticals Inc. (ACAD) Downgraded by Zacks Investment Research - July 17 at 9:40 PM logoToday's Research Reports on Stocks to Watch: ACADIA Pharmaceuticals Inc. and Mylan N.V. - July 13 at 3:47 PM logoACADIA Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACAD) : July 12, 2017 - July 12 at 3:44 PM logoACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : July 11, 2017 - July 11 at 4:26 PM logoACADIA Pharmaceuticals Inc. (ACAD) Given Consensus Recommendation of "Hold" by Brokerages - July 11 at 2:10 PM logoFaruqi & Faruqi, LLP Announces Proposed Settlement of Acadia Securities Litigation - July 11 at 1:30 AM logoWhy I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half - - July 10 at 3:26 PM logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : July 10, 2017 - July 10 at 3:26 PM logoAcadia: Order For Central Nervous Systems In Need - Seeking Alpha - July 5 at 3:34 PM logoAcadia Has A Steep Path Ahead - Seeking Alpha - July 5 at 3:34 PM logo Analysts Expect ACADIA Pharmaceuticals Inc. (ACAD) Will Announce Quarterly Sales of $19.59 Million - June 29 at 11:32 AM logoACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : June 27, 2017 - June 27 at 3:21 PM logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 27, 2017 - June 27 at 3:21 PM logoZacks: Analysts Anticipate ACADIA Pharmaceuticals Inc. (ACAD) Will Post Earnings of -$0.71 Per Share - June 27 at 10:32 AM logoACADIA Pharmaceuticals Inc. (ACAD) EVP Glenn Baity Sells 1,903 Shares - June 26 at 7:39 PM logoMinerva On Track to Initiate Phase III Schizophrenia Study - Nasdaq - June 26 at 3:35 PM logoACADIA: Is It The Right Time To Buy? - ACADIA Pharmaceuticals Inc ... - Seeking Alpha - June 26 at 3:35 PM logoWall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma - Benzinga - June 22 at 1:07 PM logoACADIA Pharmaceuticals Inc. (ACAD) Raised to Sell at BidaskClub - June 21 at 10:02 PM logo3 Value Stocks You Haven't Thought Of - June 19 at 3:17 PM logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 16, 2017 - June 16 at 3:32 PM logoACADIA Pharmaceuticals Inc. (ACAD) Given Average Rating of "Buy" by Brokerages - June 16 at 12:50 PM logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 5, 2017 - June 5 at 6:18 PM logoACADIA Pharmaceuticals Inc. (ACAD) Expected to Post Quarterly Sales of $18.44 Million - June 3 at 9:48 AM logoACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 - June 2 at 3:41 PM logoZacks: Analysts Anticipate ACADIA Pharmaceuticals Inc. (ACAD) Will Announce Earnings of -$0.71 Per Share - June 1 at 8:10 AM logoACADIA Pharmaceuticals Draws Value From Nuplazid Revenue Stream - May 31 at 11:24 AM logoACADIA Pharmaceuticals (ACAD) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow - May 24 at 3:17 PM logoPositive Clinical Results Ahead For Acadia Pharmaceuticals - Seeking Alpha - May 23 at 5:31 AM logoACADIA Pharmaceuticals Inc. (ACAD) Receives Average Recommendation of "Buy" from Analysts - May 22 at 12:25 PM logoACADIA Pharmaceuticals Inc. (ACAD) Stock Rating Reaffirmed by Rodman & Renshaw - May 22 at 10:54 AM logoLongwood Capital Partners LLC Buys ACADIA Pharmaceuticals Inc, Viveve Medical Inc, Biocryst ... - Nasdaq - May 16 at 5:40 AM logoACADIA Pharmaceuticals Inc. (ACAD) Upgraded to Hold by Zacks Investment Research - May 12 at 10:06 PM logoAcadia Pharmaceuticals: Patience Will Be Rewarded - Seeking Alpha - May 12 at 3:34 PM logoACADIA Pharmaceuticals Inc. (ACAD) to Post Q2 2017 Earnings of ($0.71) Per Share, Leerink Swann Forecasts - May 12 at 10:58 AM logoACADIA Pharmaceuticals Inc. (ACAD) Rating Reiterated by HC Wainwright - May 11 at 7:36 AM logoEdited Transcript of ACAD earnings conference call or presentation 9-May-17 9:00pm GMT - May 10 at 8:27 PM logoOversold Conditions For Acadia Pharmaceuticals (ACAD) - Nasdaq - May 10 at 3:25 PM logoThe Acadia Sell-off Is Overdone - May 10 at 3:25 PM logoACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $18.39 Million - May 10 at 11:54 AM logoACADIA Pharmaceuticals Inc. (ACAD) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS - May 10 at 12:36 AM logoBRIEF-Acadia Pharmaceuticals reports Q1 revenue $15.3 million - May 9 at 8:19 PM logo10-Q: ACADIA PHARMACEUTICALS INC - May 9 at 8:19 PM



ACADIA Pharmaceuticals (ACAD) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by Staff